Skip to content
sellModerate cluster of 210b5-1 plan

Michel Detheux sold $1.0M of ITOS

Chief Executive Officer at iTeos Therapeutics, Inc.. 104,565 shares at an average of $10.03, traded Jun 9, 2025, filed Jun 11, 2025.

Warning score
43
Value
$1.0M
104,565 shares
Holdings after
0
-72% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    CEO
    +25
  • Trade size
    $1.0M at market
    +25
  • Share of holdings sold
    Sold 72% of holdings
    +20
  • Cluster
    2 insiders selling within 14 days
    +8
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Rows in this filing

Every transaction in Form 4 0000950170-25-085047, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jun 9, 2025MOption exercise
Common Stock10b5-1
+8,400$4.30$36k144,303Jun 11, 2025
Jun 9, 2025SOpen-market sale
Common Stock10b5-1
-8,400$10.03$84k135,903Jun 11, 2025
Jun 9, 2025MOption exercise
Common Stockindirect: By MG3A10b5-1
+43,882$4.30$189k43,882Jun 11, 2025
Jun 9, 2025SOpen-market sale
Common Stockindirect: By MG3A10b5-1
-43,882$10.03$440k0Jun 11, 2025
Jun 10, 2025MOption exercise
Common Stock10b5-1
+8,400$4.30$36k144,303Jun 11, 2025
Jun 10, 2025SOpen-market sale
Common Stock10b5-1
-8,400$10.02$84k135,903Jun 11, 2025
Jun 10, 2025MOption exercise
Common Stockindirect: By MG3A10b5-1
+43,883$4.30$189k43,883Jun 11, 2025
Jun 10, 2025SOpen-market sale
Common Stockindirect: By MG3A10b5-1
-43,883$10.02$440k0Jun 11, 2025
Jun 10, 2025MOption exercise
Common Stock10b5-1
+18,000$4.30$77k153,903Jun 11, 2025
Jun 10, 2025MOption exercise
Common Stockindirect: By MG3A10b5-1
+94,027$4.30$404k94,027Jun 11, 2025
Jun 9, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-8,400$0.00$026,400Jun 11, 2025
Jun 9, 2025MOption exercise
Stock Option (Right to Buy)derivativeindirect: By MG3A10b5-1
-43,882$0.00$0137,913Jun 11, 2025
Jun 10, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-8,400$0.00$018,000Jun 11, 2025
Jun 10, 2025MOption exercise
Stock Option (Right to Buy)derivativeindirect: By MG3A10b5-1
-43,883$0.00$094,030Jun 11, 2025
Jun 10, 2025MOption exercise
Stock Option (Right to Buy)derivative10b5-1
-18,000$0.00$00Jun 11, 2025
Jun 10, 2025MOption exercise
Stock Option (Right to Buy)derivativeindirect: By MG3A10b5-1
-94,027$0.00$03Jun 11, 2025

Related signals

Other insiders at iTeos Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
43Moderate
ITOSsell 210b5-1
iTeos Therapeutics, Inc.
Michel Detheux
Chief Executive Officer
$1.6M
156,847 shares
-109%
33Weak
ITOSsell 210b5-1
iTeos Therapeutics, Inc.
David Hallal
director
$1.2M
114,682 shares
-300%
42Moderate
ITOSbuy
iTeos Therapeutics, Inc.
EcoR1 Capital, LLC
owner
$39M
4,958,978 shares
+87%
53Moderate
ITOSsell 3
iTeos Therapeutics, Inc.
MPM BioVentures 2014, L.P.
other
$5.1M
630,191 shares
-23%
53Moderate
ITOSsell 3
iTeos Therapeutics, Inc.
Ansbert Gadicke
other
$8.3M
1,031,931 shares
-23%
53Moderate
ITOSsell 3
iTeos Therapeutics, Inc.
Mpm Bioventures 2018, L.p.
other
$5.1M
630,191 shares
-23%
31Weak
ITOSbuy
iTeos Therapeutics, Inc.
Matthew Gall
Chief Financial Officer
$39k
5,000 shares
+8%
34Weak
ITOSbuy
iTeos Therapeutics, Inc.
Matthew Gall
Chief Financial Officer
$42k
5,000 shares
+35%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.